The Efficacy of Cone-beam Computed Tomography-guided Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Survival: A Systematic Review

Overview

Journal J Clin Imaging Sci

Specialty Radiology

Date 2024 Aug 7

PMID 39108320

Authors

Levent Akman Solim

Duygu Atasoy

Thomas J Vogl

Affiliations

Soon will be listed here.

Abstract

Cone-beam computed tomography (CBCT)-guided transcatheter arterial chemoembolization (TACE) represents an alternative treatment option for advanced hepatocellular carcinoma (HCC) patients, yet a comprehensive evaluation of CBCT guidance on this procedure and CBCT's impact on patient survival remains lacking. We aimed to assess the efficacy and benefits of CBCT-guided TACE in improving survival outcomes for patients with HCC and show the importance of CBCT in interventional radiology. Meta-analysis was conducted to evaluate CBCT-guided TACE compared to conventional TACE in the treatment of HCC. PubMed and Cochrane library databases were searched for studies published. Outcomes of interest included 1- or 3-year local progression-free survival (LPFS) rates, overall survival (OS) rates, and tumor response results. A total of eight studies were included in the meta-analysis, comprising 1176 patients. The analysis showed that CBCT-guided TACE improved 1-year LPFS (odds ratio [OR] = 2.81, < 0.001), 3-year (OR = 4.42, = 0.002), and the 3-year OS rates (OR = 3.03, Confidence Interval = 1.65-11.80, = 0.14) compared to conventional TACE. CBCT-guided TACE enhances survival outcomes for patients with HCC; by addressing this research gap, our study endeavors to encourage clinicians and researchers to pursue this medical technology by providing a robust synthesis of current evidence.

Citing Articles

Another year of Service to the Global Radiology Community.

Dogra V J Clin Imaging Sci. 2025; 15:4.

PMID: 39916768 PMC: 11801424. DOI: 10.25259/JCIS_5_2025.

References

Bzeizi K, Arabi M, Jamshidi N, Albenmousa A, Sanai F, Al-Hamoudi W . Conventional Transarterial Chemoembolization Versus Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Cancers (Basel). 2021; 13(24). PMC: 8699068. DOI: 10.3390/cancers13246172. View

Ayyub J, Dabhi K, Gohil N, Tanveer N, Hussein S, Pingili S . Evaluation of the Safety and Efficacy of Conventional Transarterial Chemoembolization (cTACE) and Drug-Eluting Bead (DEB)-TACE in the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review. Cureus. 2023; 15(7):e41943. PMC: 10351914. DOI: 10.7759/cureus.41943. View

Lee J, Lee I, Kim H, Park B, Kim B, Park J . Efficacy and safety of transarterial chemoembolisation with cone-beam CT in patients with hepatocellular carcinoma within the Milan criteria: a retrospective cohort study. Clin Radiol. 2019; 74(5):407.e19-407.e28. DOI: 10.1016/j.crad.2019.01.024. View

Wang Z, Lin M, Lesage D, Chen R, Chapiro J, Gu T . Three-dimensional evaluation of lipiodol retention in HCC after chemoembolization: a quantitative comparison between CBCT and MDCT. Acad Radiol. 2014; 21(3):393-9. PMC: 3979929. DOI: 10.1016/j.acra.2013.11.006. View

Couri T, Pillai A . Goals and targets for personalized therapy for HCC. Hepatol Int. 2019; 13(2):125-137. DOI: 10.1007/s12072-018-9919-1. View

Wen N, Cai Y, Li F, Ye H, Tang W, Song P . The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update. Biosci Trends. 2022; 16(1):20-30. DOI: 10.5582/bst.2022.01061. View

Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag C, Vignat J . Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022; 77(6):1598-1606. PMC: 9670241. DOI: 10.1016/j.jhep.2022.08.021. View

Salem R, Gordon A, Mouli S, Hickey R, Kallini J, Gabr A . Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology. 2016; 151(6):1155-1163.e2. PMC: 5124387. DOI: 10.1053/j.gastro.2016.08.029. View

Schulz B, Heidenreich R, Heidenreich M, Eichler K, Thalhammer A, Naeem N . Radiation exposure to operating staff during rotational flat-panel angiography and C-arm cone beam computed tomography (CT) applications. Eur J Radiol. 2012; 81(12):4138-42. DOI: 10.1016/j.ejrad.2012.01.010. View

10.

Bannangkoon K, Hongsakul K, Tubtawee T . Impact of cone-beam computed tomography with automated feeder detection software on the survival outcome of patients with hepatocellular carcinoma during treatment with conventional transarterial chemoembolization. BMC Gastroenterol. 2021; 21(1):419. PMC: 8574007. DOI: 10.1186/s12876-021-02004-z. View

11.

Choi J, Kim H, Lee J, Yu S, Cho E, Kim M . Cone Beam CT-Guided Chemoembolization of Probable Hepatocellular Carcinomas Smaller than 1 cm in Patients at High Risk of Hepatocellular Carcinoma. J Vasc Interv Radiol. 2017; 28(6):795-803.e1. DOI: 10.1016/j.jvir.2017.01.014. View

12.

Orlacchio A, Roma S, DellOlio V, Crociati S, Lenci I, Francioso S . Role of Cone-Beam CT in the Intraprocedural Evaluation of Chemoembolization of Hepatocellular Carcinoma. J Oncol. 2021; 2021:8856998. PMC: 7997764. DOI: 10.1155/2021/8856998. View

13.

Paul J, Chacko A, Mbalisike E, Vogl T . Cone-beam computed tomography imaging: therapeutic staff dose during chemoembolisation procedure. J Radiol Prot. 2015; 34(4):843-51. DOI: 10.1088/0952-4746/34/4/843. View

14.

Miyayama S, Yamashiro M, Ikuno M, Okumura K, Yoshida M . Ultraselective transcatheter arterial chemoembolization for small hepatocellular carcinoma guided by automated tumor-feeders detection software: technical success and short-term tumor response. Abdom Imaging. 2014; 39(3):645-56. DOI: 10.1007/s00261-014-0094-0. View

15.

Kim H, Chung J, Lee W, Jae H, Park J . Recognizing extrahepatic collateral vessels that supply hepatocellular carcinoma to avoid complications of transcatheter arterial chemoembolization. Radiographics. 2005; 25 Suppl 1:S25-39. DOI: 10.1148/rg.25si055508. View

16.

Caselitz M, Masche N, Flemming P, Stern C, Manns M, Wagner S . [Prognosis of hepatocellular carcinoma according to new staging classifications]. Dtsch Med Wochenschr. 2004; 129(33):1725-30. DOI: 10.1055/s-2004-829023. View

17.

Savic L, Chen E, Nezami N, Murali N, Hamm C, Wang C . Conventional vs. Drug-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma-A Propensity Score Weighted Comparison of Efficacy and Safety. Cancers (Basel). 2022; 14(23). PMC: 9738175. DOI: 10.3390/cancers14235847. View

18.

Fronda M, Mistretta F, Calandri M, Ciferri F, Nardelli F, Bergamasco L . The Role of Immediate Post-Procedural Cone-Beam Computed Tomography (CBCT) in Predicting the Early Radiologic Response of Hepatocellular Carcinoma (HCC) Nodules to Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE). J Clin Med. 2022; 11(23). PMC: 9740708. DOI: 10.3390/jcm11237089. View

19.

Iwazawa J, Ohue S, Hashimoto N, Muramoto O, Mitani T . Survival after C-arm CT-assisted chemoembolization of unresectable hepatocellular carcinoma. Eur J Radiol. 2012; 81(12):3985-92. DOI: 10.1016/j.ejrad.2012.08.012. View

20.

Lucatelli P, Guiu B . 2022 Update of BCLC Treatment Algorithm of HCC: What's New for Interventional Radiologists?. Cardiovasc Intervent Radiol. 2022; 45(3):275-276. DOI: 10.1007/s00270-021-03047-1. View